Title
Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation.

Permalink
https://escholarship.org/uc/item/6kd5p3jq

Journal
The Journal of experimental medicine, 186(6)

ISSN
0022-1007

Authors
Bozza, PT
Yu, W
Penrose, JF
et al.

Publication Date
1997-09-01

DOI
10.1084/jem.186.6.909

Peer reviewed
Eosinophil Lipid Bodies: Specific, Inducible Intracellular Sites for Enhanced Eicosanoid Formation

By Patricia T. Bozza,*† Wengui Yu,*† John F. Penrose,§ Ellen S. Morgan,*§ Ann M. Dvorak,*§ and Peter F. Weller*‡

From the *H arvard Th orndike Laboratory and Charles A. D ana R earch Institute, †D epartment of M edicine and §D epartment of Pathology, Beth Israel D eaconess M edical C enter, and ‡D epartment of M edicine, Brigham and W omen's H ospital and H arvard M edical School, Boston, M assachusetts 02215

Summary

The specific intracellular sites at which enzymes act to generate arachidonate-derived eicosanoid mediators of inflammation are uncertain. We evaluated the formation and function of cytoplasmic lipid bodies. Lipid body formation in eosinophils was a rapidly (<1 h) inducible response which was platelet-activating factor (PAF) receptor-mediated, involved signaling through protein kinase C, and required new protein synthesis. In intact and enucleated eosinophils, the PAF-induced increases in lipid body numbers correlated with enhanced production of both lipoxygenase- and cyclooxygenase-derived eicosanoids. All principal eosinophil eicosanoid-forming enzymes, 5-lipoxygenase, leukotriene C_4 synthase, and cyclooxygenase, were immunolocalized to native as well as newly induced lipid bodies in intact and enucleated eosinophils. Thus, lipid bodies are structurally distinct, inducible, nonnuclear sites for enhanced synthesis of paracrine eicosanoid mediators of inflammation.

Leukotrienes (LT), together with PGs, thromboxanes, and lipoxins, are the major constituents of a group of biologically active oxygenated fatty acids known as eicosanoids. Eicosanoids function as paracrine mediators of inflammation as well as intracellular signals. Eicosanoids play major roles in inflammatory responses and have been implicated in the pathogenesis of many inflammatory diseases, including asthma, psoriasis, rheumatoid arthritis, and inflammatory bowel disease (1, 2). The synthesis of eicosanoids is catalyzed by lipoxygenases (LOs) (for LTs, hydroxyeicosatetraenoic acids, and lipoxins) and PG endoperoxide H synthases, also known as cyclooxygenases (for PGs and thromboxanes). Although the enzymatic pathways for eicosanoid formation are well understood, the intracellular sites of action of these enzymes and the cellular sources of arachidonic acid remain less clear. Recent studies have focused on the intracellular localization of eicosanoid-forming enzymes. Cyclooxygenases (COXs) are associated with cellular membranes, including the endoplasmic reticulum and nuclear membrane (3–5). In contrast, 5-LO has been localized to the cytoplasm, the perinuclear membrane, and the euchromatin within the nucleus, according to the cell and activation state used (6–10). While translocation from cytosol to membranes may facilitate interactions of cytosolic enzymes with membrane-bound arachidonate, there is increasing evidence that specific compartmentalization of eicosanoid formation within cells may relate to the different autocrine and paracrine functions of eicosanoids (5, 11). Novel, potential sites for paracrine eicosanoid production within inflammatory cells are lipid bodies.

Lipid bodies are lipid-rich cytoplasmic inclusions which are candidates to play a major role in the formation of eicosanoid mediators during inflammation. Lipid bodies characteristically develop in vivo in cells associated with inflammation; including leukocytes from joints of patients with inflammatory arthritis (12–14), the airways of patients with acute respiratory distress syndrome (15), and casein- or lipopolysaccharide-elicited guinea pig peritoneal exudates (16). In eosinophils, increased lipid body numbers have been observed in patients with the hypereosinophilic syndrome (HES) (17, 18), in biopsies from Crohn's disease (19), and the blood of airway antigen-challenged asthmatic patients (Weller, P.F., unpublished observations). Lipid bodies are sites of esterified arachidonate localization in cells including neutrophils and eosinophils (17, 20). In human eosinophils, by electron microscopic autoradiography and biochemical analysis of purified lipid bodies, lipid bodies have been shown to incorporate [3H]arachidonic acid into specific phospholipid classes (17). In addition, up-
stream enzymes involved in arachidonic acid release, MAP kinases, and cytosolic phospholipase A$_2$ (cPLA$_2$) (Yu, W., P.T. Bozza, D.M. Tizik, J.P. Gray, J. Cassara, A.M. Dvorak, and P.F. Welter, manuscript submitted for publication) as well as COX (21–23) have been localized to lipid bodies in several types of leukocytes and other cells. Moreover, we have demonstrated recently that stimuli-elicited compartmentalization of lipids to form new lipid bodies is associated with enhanced capacity for eicosanoid generation, suggesting that the cellular responses leading to lipid body formation may be important in the formation of eicosanoid mediators of inflammation (24, 25).

In this study we have evaluated mechanisms involved in lipid body formation and function in human eosinophils. We demonstrate that platelet-activating factor (PAF) rapidly induces lipid body formation in eosinophils in a receptor-dependent fashion, with subsequent activation of protein kinase C (PKC) and protein synthesis. By means of immunocytochemistry, electron microscopic immunogold localization, and/or subcellular fractionation with Western blotting, the major eicosanoid-forming enzymes of eosinophils, 5-LO, LTC$_4$ synthase, and COX, are present within native and induced eosinophil lipid bodies. Furthermore, PAF-elicited lipid body formation is associated with enhanced generation of eicosanoids by both intact and enucleated eosinophils, suggesting that lipid bodies may be important inducible sites for enhanced paracrine eicosanoid mediator production during inflammation.

### Materials and Methods

PAF (1-0-hexadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine), lyso-PAF (1-0-αkyl-sn-glycerol-3-phosphorylcholine), chelerythrine, pertussis toxin, actinomycin D, cytochalasin B, and A23187 were from Calbiochem Novabiochem Corp. (La Jolla, CA). Cycloheximide was obtained from Sigma Chemical Co. (St. Louis, MO). 1-acetyl-2-(7- octyl) BODIPY TM-1-pentanoyl)-sn-glycerol was obtained from Molecular Probes (Eugene, OR). W E B 2086 was a gift from Boehringer-Ingelheim (Ingelheim, Germany) and recombinant 5-LO was a gift of Dr. Jilly Evans, Merck Frosst (Pointe Claire-Dorval, Quebec, Canada). Antibodies used included rabbit anti-5-LO (Molecular Probes (Eugene, OR)). W E B 2086 was a gift from Boehringer-Ingelheim (Ingelheim, Germany) and recombinant 5-LO was a gift of Dr. Jilly Evans, Merck Frosst (Pointe Claire-Dorval, Quebec, Canada). Antibodies used included rabbit anti-5-LO (Molecular Probes (Eugene, OR)).

Human Eosinophil Purification. Human eosinophils were purified as previously described (27). In brief, fresh human blood was obtained by venipuncture from healthy adult volunteers and collected into acidified citrate. After addition of 6% dextran 70 (M c-Gaw, Irvine, CA), RBCs were allowed to sediment for 1 h at room temperature. The leukocyte-rich supernatant was overlaid onto an equal volume of ficoll-paque gradient (Pharmacia Biotech, Piscataway, NJ) and centrifuged at 400 g for 20 min. Granulocytes were recovered from the pellet and washed in Ca$^{2+}$/M g$^{2+}$ free HBSS. R esidual R BCs were lysed with hypotonic saline. Eosinophils (>95% pure) were negatively selected with anti-CD16 immunomagnetic beads (Milteny Bioteci Inc., Auburn, CA) to remove neutrophils using the MACS system (Milteny Biotec).

Cytoplasm Preparation. Cytoplasts were prepared by the method of R os et al. (28). Briefly, eosinophils were mixed with 12.5% (wt/vol) ficoll 70 containing 20 μM cytochalasin B and incubated for 5 min at 37°C. After incubation, eosinophils were layered over a discontinuous gradient of 16% and 25% ficoll 70 containing 20 μM cytochalasin B which had been prewarmed to 37°C. The cells were centrifuged at 82,000 g for 35 min at 35°C. Cytoplasts (>90% pure) were recovered from the layer formed at the 12.5%/16% and 16%/25% ficoll interfaces and washed five times in Ca$^{2+}/M$ g$^{2+}$-free HBSS. Nuclei and granule containing cytoplasts were in the pellet.

Lipid Body Induction and Treatments. Human eosinophils (10$^6$ cells/ml) were incubated with varying concentrations of PAF, lyso-PAF, or vehicle at 37°C in a 5% CO$_2$, 95% O$_2$ atmosphere; after the incubation period eosinophils (10$^6$/slide) were cytocentrifuged (550 rpm, 5 min) onto glass slides. During inhibitor studies, eosinophils were pretreated for 1 h with varying concentrations of receptor antagonist, enzyme inhibitors, or vehicle as indicated. When PKC and protein synthesis inhibitors were used, the preincubation time was reduced to 30 min to avoid toxic effect to the cells. T he cell viability, determined by trypan blue dye exclusion at the end of each experiment, was always >90%. In selected experiments, apoptosis of eosinophils was monitored by fluorescence microscopy of cells exposed to propidium iodide (10 μg/ml) and annexin V-FITC (1 μg/ml) according to the manufacturer's recommendation (Apopert apoptosis kit; Clontech, Palo Alto, CA). Stock solutions for A23187, W E B 2086, and actinomycin D were prepared in DM SO and stored at −20°C. Aliquots were diluted in Ca$^{2+}/M$ g$^{2+}$-free HBSS to the indicated concentration immediately before use. T he final DM SO concentration was always <0.1% and had no effect on lipid body numbers. Cycloheximide, chelerythrine, and pertussis toxin were diluted in Ca$^{2+}/M$ g$^{2+}$-free HBSS. Stock solutions of PAF and lyso-PAF were prepared in Ca$^{2+}/M$ g$^{2+}$-free HBSS containing 0.1% BSA.

Lipid Body Staining and Enumeration. While still moist, eosinophils on cytopsin slides were fixed in 3.7% formaldehyde in Ca$^{2+}/M$ g$^{2+}$-free HBSS, pH 7.4, rinsed in 0.1 M cacodylate buffer, pH 7.4, stained in 1.5% O S O$_4$ (30 min), rinsed in diH$_2$O, immersed in 1% thiacarbodiazide (5 min), rinsed in 0.1 M cacodylate buffer, reained in 1.5% O S O$_4$ (3 min), rinsed in diH$_2$O, and then dried and mounted. The morphology of fixed cells was observed, and lipid bodies were enumerated by phase-contrast microscopy with an ×100 objective lens in 50 consecutively scanned eosinophils. LTC$_4$ and PG$_E_2$ Measurement. Human eosinophils or eosinophil cytoplasts (10$^6$ cells/ml) were stimulated with PAF (10$^{-8}$–10$^{-6}$ M) or vehicle at 37°C for 1 h for lipid body formation. After incubations, samples were taken for lipid body enumeration and eicosanoids were washed in Ca$^{2+}/M$ g$^{2+}$-free HBSS. Eosinophils or cytoplasts were resuspended in 1 ml of HBSS containing Ca$^{2+}/M$ g$^{2+}$ and then stimulated with A23187 (0.5 μM) for 15 min. Reactions were stopped on ice, and the samples were centrifuged at 500 g for 10 min at 4°C. LTC$_4$ and PG$_E_2$ in the supernatants were assayed by ELISA according to the manufacturer's instructions (Cayman Chemical Co., Inc.).

Immunogold Staining. Electron microscopic preparation of samples and immunogold staining was performed as described previously (21, 29). In brief, eosinophils were fixed in suspension for 1 h at 20°C in a dilute mixture of aldehydes in sodium cacodylate buffer, washed overnight at 4°C, centrifuged through molten agar, postfixed in collidine-buffered osmium tetroxide for 2 h at 20°C, stained en bloc with uranyl acetate, dehydrated in a graded series of alcohols, infiltrated, and embedded and polymerised.
alyzed in a propylene oxide-Epon sequence. Postembedding immunogold staining was performed in the following sequence: (a) freshly cut thin sections on either gold or nickel grids either unmasked in 2% sodium metaperiodate for 30 min or permeabilized on 0.1% Triton X-100 in 0.1 M Tris-buffered saline, pH 7.6, for 10 min; (b) three washes of 10 min each in Tris-buffered saline containing 0.1% BSA (TBBS-BSA); (c) block with TBBS-BSA containing 5% normal goat serum for 30 or 60 min; (d) incubation at room temperature for 60 min in a 1:10 dilution of rabbit polyclonal antiserum to 5-LO (LO32 from Merck Frosst) in TBBS-BSA; (e) incubation for 120 min at room temperature in a 1:20 dilution of 20-nm gold-labeled goat anti–rabbit IgG (E.Y. Laboratories, Inc., San Mateo CA); (f) two washes of 10 min each in TBBS-BSA; (g) two washes of 5 min in distilled water and dried overnight, and (h) staining with dilute lead citrate for 10 min. N onimmune rabbit serum or 5-LO solid phase absorbed anti–5-LO antiserum, prepared as described (19), at the same dilution as the 5-LO antiserum, were used as controls.

Immunocytochemistry. Human eosinophils or eosinophil cytoplasts (10^6 cells/ml) were stimulated with PAF (10^{-6} M) at 37°C for 1 h for lipid body formation. In some experiments, 1 μM of the fluorescent fatty acid–containing diglyceride, 1-acyl-2-(7-tocetyl BODIPY)^+@-1-pentanoyl)-sn-glycerol (30), was added to the incubation in order to fluorescently label lipid bodies. After the incubation, cells were washed twice in Ca^2+ and Mg^2+–free HBSS, cytospun onto slides, and fixed in 3% formaldehyde at room temperature for 10 min. Fixed cells were permeabilized with 0.05% saponin/HBSS solution and then blocked with 10% nonfat dry milk. Detection of antigen–antibody complexes was performed by Supersignal chemiluminescence (Pierce Chemical Co., Rockford, IL). Samples (15 μg) of each fraction were then prepared in reducing and denaturing conditions and separated by electrophoresis in 10% SDS-PAGE gels. After transfer onto nitrocellulose membranes, nonspecific binding sites were blocked with 5% nonfat dry milk (Bio-Rad, Hercules, CA) in Tris-buffered saline–Tween (TBST; 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 0.1% Tween 20) at room temperature for 1 h. The membranes were then probed with anti-5-LO serum (1:5000 dilution) followed by horseradish peroxidase-conjugated secondary antibodies (1:5000 dilution) in TBST with 2% nonfat dry milk. Detection of antigen–antibody complexes was performed by Supersignal chemiluminescence (Pierce Chemical Co.).

Results. R esults were expressed as mean ± SEM and were analyzed statistically by means of ANOVA followed by the Newman-Keuls Student test with the level of significance set at P < 0.05. Correlation coefficients were determined by linear regression, and correlation analysis was performed by Fisher’s r to z transformation with the level of significance set at P < 0.05.

Results

Mechanisms of PAF-induced Lipid Body Formation in Eosinophils. Lipid bodies, although small in number, are normal constituents of leukocytes, including eosinophils. Increased lipid body formation occurs in vivo and can be induced in vitro. In eosinophils obtained from normal donors, within 1 h PAF stimulated a dose-dependent induction of lipid body formation in vitro (Fig. 1A). In response to 1 μM PAF, lipid body numbers persisted at similar numbers at 1, 4, and 8 h (14.1 ± 6%, 15.9 ± 0.7%, and 9.5 ± 0.5 lipid bodies ± SEM/eosinophil, respectively) with no evidence of enhanced cell death or apoptosis (<7% apoptotic eosinophils at 8 h with and without PAF stimulation). Several findings indicated that the actions of PAF were receptor mediated. First, lyso-PAF failed to induce lipid body formation (Fig. 1A). Second, the PAF-receptor antagonist WEB 2086 dose-dependently inhibited PAF-induced lipid body formation (Fig. 1B). Moreover, earlier treatment of cells with pertussis toxin (100 ng/ml, 1 h before PAF) to block PAF-receptor G-protein–mediated signals completely prevented PAF-induced lipid body formation in human eosinophils (Fig. 1B).

Additional intracellular signaling pathways involved in PAF-induced lipid body formation in human eosinophils were studied. As shown in Table 1, staurosporine (1–10 μM) and H-7 (25–50 μM) significantly inhibited the in-
Increases in lipid body numbers induced by PAF in human eosinophils, thus suggesting a role for PKC in this process. The involvement of PKC in PAF-induced lipid body formation was confirmed by the ability of two selective PKC inhibitors, chelerythrine (1–10 μM) and calphostin C (0.5–1 μM), to almost completely block the induction of lipid bodies (Table 1). Pretreatment with inhibitors of mRNA and protein synthesis, actinomycin D (1 μM) and cycloheximide (1 μM), respectively, significantly inhibited PAF-induced lipid body formation (Table 1), suggesting that eosinophil lipid body induction depends on gene expression and de novo protein synthesis.

Immunolocalization of Eicosanoid-forming Enzymes to Eosinophil Lipid Bodies. Since human eosinophils form LTC4 as

Table 1. Effects of PKC and Protein Synthesis Inhibitors on PAF-induced Lipid Body Formation in Eosinophils

| Treatment       | Dose (μM) | Lipid bodies (mean ± SEM) / eosinophils | Percentage of inhibition |
|-----------------|-----------|----------------------------------------|--------------------------|
| Staurosporine   | 0         | 21.8 ± 2.1                             | -                        |
|                 | 1         | 14.9 ± 1.4*                            | 58                       |
|                 | 10        | 12.8 ± 0.9*                            | 83                       |
| H-7             | 0         | 21.8 ± 2.1                             | -                        |
|                 | 25        | 14.9 ± 1.0*                            | 58                       |
|                 | 50        | 11.8 ± 1.1                             | 75                       |
| Calphostin      | 0         | 21.8 ± 2.1                             | -                        |
|                 | 0.5       | 13.1 ± 1.3*                            | 65                       |
|                 | 1         | 11.6 ± 0.9*                            | 85                       |
| Chelerythrine   | 0         | 21.8 ± 2.1                             | -                        |
|                 | 1         | 15.7 ± 1.6*                            | 51                       |
|                 | 10        | 13.0 ± 1.3*                            | 73                       |
| Actinomycin     | 0         | 11.8 ± 0.8                             | -                        |
|                 | 1         | 7.9 ± 0.3*                             | 60                       |
| Cycloheximide   | 0         | 11.8 ± 0.8                             | -                        |
|                 | 1         | 7.4 ± 0.2*                             | 68                       |

Eosinophils (10⁶/ml) were pretreated with PKC or protein synthesis inhibitors for 30 min and then stimulated with PAF (1 μM) or vehicle for 1 h. Results are mean ± SEM from three to five experiments with different donors. Percentage of inhibition was calculated using the following formula: percentage of inhibition = 100 – (net No. of PAF-induced lipid bodies in treatment group × 100) / (net No. of PAF-induced lipid bodies with PAF alone). Basal mean numbers of lipid bodies ranged from 5.3 to 9.8/eosinophil with different donors and have been subtracted to determine the net induced lipid body numbers. *Statistically significant differences between agonists alone and treated groups.
their principal 5-LO pathway product and form lesser amounts of COX-derived eicosanoids, we evaluated whether the key eicosanoid-forming enzymes were localized at eosinophil lipid bodies, both in naturally formed lipid bodies in eosinophils from HES patients and in lipid bodies induced to form in vitro. The compartmentalization of 5-LO, LTC₄ synthase, and COX to lipid bodies was analyzed by immunocytochemistry using conditions of cell fixation and permeabilization that prevent dissolution of lipid bodies. Human eosinophils were stimulated with PAF (1 μM, for 1 h) to induce lipid body formation, and lipid bodies were visualized by endogenous labeling with the fluorescent fatty acid-containing diglyceride, 1-acyl-2-(7-octyl BODIPY™-1-pentanoyl)-sn-glycerol (1 μM, for 1 h). Fluorescent fatty acid-labeled lipid bodies were visualized as green punctate intracytoplasmic inclusions under FITC excitation. (B) With specific anti-5-LO rabbit antiserum and glucose-oxidase immunocytochemistry, there was 5-LO staining diffusely in the cytoplasm as well as at punctate lipid bodies (which matched those in A). (D) With control nonimmune rabbit serum there was no lipid body or cytoplasmic staining.

**Figure 2.** Immunolocalization of 5-LO to lipid bodies of human eosinophils. (A and C) Human eosinophils from normal volunteers were incubated with PAF (1 μM, for 1 h) to induce lipid body formation, and lipid bodies were visualized by endogenous labeling with the fluorescent fatty acid-containing diglyceride, 1-acyl-2-(7-octyl BODIPY™-1-pentanoyl)-sn-glycerol (1 μM, for 1 h). Fluorescent fatty acid-labeled lipid bodies were visualized as green punctate intracytoplasmic inclusions under FITC excitation. (B) With specific anti-5-LO rabbit antiserum and glucose-oxidase immunocytochemistry, there was 5-LO staining diffusely in the cytoplasm as well as at punctate lipid bodies (which matched those in A). (D) With control nonimmune rabbit serum there was no lipid body or cytoplasmic staining.
from eosinophilic donors contained lipid bodies exhibiting specific anti-5-LO staining by glucose oxidase immunocytochemistry (not shown). The immunolocalization of 5-LO within lipid bodies was confirmed by immunogold electron microscopy. Freshly isolated, unstimulated eosinophils from an HES donor, examined by postembedding immunogold with anti-5-LO antisera, contained lipid bodies which were extensively gold labeled with 20 nm gold particles (Fig. 3, A and C). Substitution of the specific anti-5-LO antibody with either control 5-LO absorbed anti-5-LO antiserum (Fig. 3 B) or nonimmune serum (Fig. 3 D) yielded no staining of lipid bodies.

In human eosinophils, LTC4 is the predominant 5-LO product (31). Recently, human LTC4 synthase, the enzyme responsible for conjugating glutathione to form LTC4, has been purified and cloned (26, 32, 33). Using an affinity-purified rabbit anti-LTC4 synthase IgG (26), this LTC4-forming enzyme was localized directly to lipid bodies. Eosinophils induced to form lipid bodies and stained with anti-LTC4 synthase IgG showed focal cytoplasmic staining (Fig. 4 B) which matched the fluorescent fatty acid-labeled lipid bodies (Fig. 4 A). Likewise, eosinophils from an HES donor showed LTC4 synthase localization at native lipid bodies (not shown). The enzyme COX was also shown to colocalize to PAF-induced lipid bodies in eosinophils (Fig. 4, C and D), in agreement with previous immunogold electron microscopic localization of COX to lipid bodies in freshly isolated eosinophils (21). Specificity of anti-COX and anti-LTC4 staining was demonstrated by the absence of immunoreactivity when nonimmune rabbit IgG was used instead of the specific primary antibody, under conditions where fluorescent fatty acid-labeled lipid bodies were present (Fig. 3, E and F). Thus, 5-LO, LTC4 synthase and COX were present at lipid bodies within 1 h of their induction as well as in naturally formed lipid bodies in eosinophils from eosinophilic donors.

Involvement of Lipid Bodies in Enhanced Generation of Eicosanoids by PAF-stimulated Eosinophils. Because eosinophil lipid bodies are sites of intracellular localization of eicosanoid-forming enzymes (Figs. 2–4) and also stores of eicosanoid-precursor arachidonic acid (17), we analyzed whether PAF-induced increases in lipid body numbers in eosinophils would correlate with increased LTC4 and PGE2 production by human eosinophils. After eosinophils were incubated with various concentrations of PAF for 1 h, lipid bodies were enumerated and replicate eosinophils were stimulated with A23187 (0.5 μM). As shown in Fig. 5, PAF dose-dependently induced concordant increases in both lipid body numbers and priming for enhanced LTC4 (Fig. 5 A) and PGE2 (Fig. 5 B) generation. Increases in lipid body numbers correlated with enhanced production of each eicosanoid (r = 0.97, P < 0.03, r = 0.99, P < 0.001 for LTC4 and PGE2, respectively). If the hypothesis that lipid bodies have roles in enhanced eicosanoid formation is correct, then inhibition of lipid body formation should result in suppressed eicosanoid formation. To test this hypothesis, we used the inhibitors of protein synthesis, actinomycin D and cycloheximide, because these compounds were effective in blocking lipid body formation induced by PAF (Table 1). Pretreatment of eosinophils with actinomycin D (1 μM) or cycloheximide (1 μM) inhibited not only PAF-induced lipid body formation, but also priming for LTC4 (by 70 and 40% for actinomycin and cycloheximide, respectively) and PGE2 (by 40 and 54% for actinomycin and cycloheximide, respectively) release by eosinophils, under conditions where these inhibitors failed to inhibit calcium ionophore-induced LTC4 and PGE2 in cells not prestimulated with PAF (not shown).

Lipid Body Formation, Eicosanoid-forming Enzyme Localization, and Priming for Enhanced Generation of Eicosanoids by PAF-stimulated Enucleated Eosinophils. Recently, several studies have focused on the role of the perinuclear environment...
as a site of eicosanoid-forming enzyme localization and eicosanoid generation (5, 11). In order to evaluate whether lipid bodies may function as nuclear-independent alternative sites of eicosanoid production, we generated enucleated eosinophilic cytoplasts, by modifying the technique of Roos et al. (28) for cytoplast formation in neutrophils. A typical eosinophilic cytoplast preparation, devoid of nuclei and specific granules, is shown in Fig. 6. After freshly isolated eosinophils (Fig. 6 A) were layered over a discontinuous gradient of Ficoll 70 containing 20 μM cytochalasin B and subjected to centrifugation, cytoplasts (>90% pure, Fig. 6 B) were formed by the fusion of the plasma membrane around the cytoplasmic part of the cell and recovered from the layers formed at the 12.5/16% and 16/25% Ficoll interfaces. The nuclei and granules, also surrounded by plasma membrane, migrated to the bottom of the gradient (Fig. 6 C) and constituted karyoplasts.

Similar to the reaction observed with intact eosinophils, PAF induced a dose-dependent formation of lipid bodies in eosinophilic cytoplasts (Fig. 7). WEB 2086 (10 μM, 1 h before PAF) blocked this PAF-induced lipid body formation by 84%, indicating that PAF-induced lipid body formation was receptor-mediated in cytoplasts as in intact eosinophils. Moreover, PAF-induced lipid body formation in nuclei-free cytoplasts strongly correlated with increased LTC₄ (Fig. 7 A) and PGE₂ (Fig. 7 B) production after submaximal stimulation with A23187 (0.5 μM). The karyoplast fraction of eosinophils was also able to generate increased amounts of LTC₄, but not PGE₂, upon stimulation (data not shown).

**Figure 4.** Immunolocalization of LTC₄ synthase and COX to lipid bodies of human eosinophils. Human eosinophils from normal volunteers were incubated with PAF (1 μM, for 1 h) to induce lipid body formation, and lipid bodies were visualized by endogenous labeling with the fluorescent fatty acid-containing diglyceride, 1-acyl-2-(7-octyl BODIPY™)-1-pentanoyl)-sn-glycerol (1 μM, for 1 h). Fluorescent fatty acid–labeled lipid bodies were visualized as green punctate intracytoplasmic inclusions under FITC excitation (A, C, and E). LTC₄ synthase (B) and COX (D) were localized to lipid bodies using anti-LTC₄ and anti-COX, respectively, affinity-purified rabbit IgG, and glucose-oxidase immunocytochemistry. Rabbit IgG was used as a control (F). Lipid bodies exhibit dark punctate staining in B and D which matches fluorescent lipids in A and C, respectively. (Some fluorescent lipid bodies are out of the plane of focus and not visible.)
The presence of 5-LO, LTC₄ synthase, and COX within eosinophil cytoplasts was analyzed by glucose oxidase immunocytochemical staining after stimulation of eosinophil cytoplasts with PAF (1 μM, for 1 h) to induce lipid body formation. Cytoplasts, stained with anti-5-LO polyclonal antiserum (Fig. 6 D), affinity-purified rabbit anti-LTC₄ synthase IgG (Fig. 6 E) or affinity-purified rabbit anti-COX IgG (Fig. 6 F), showed the punctate cytoplasmic immunocytochemical staining indicative of lipid body localization. The specificities of immunocytochemical stainings were demonstrated by the absence of immunoreactivity when nonimmune rabbit IgG (Fig. 5 G) or normal rabbit serum (Fig. 5 H) were used instead of specific antibody.

**Discussion**

In this study we report a series of complementary observations in human eosinophils which provide evidence for novel roles of lipid bodies as specific inducible sites of paracrine eicosanoid mediator formation. First, lipid bodies, prominent in vivo in eosinophils and other leukocytes associated with inflammatory reactions, can be induced to rap-

**Figure 5.** PAF-induced both lipid body formation and priming for LTC₄ (A) and PGE₂ (B) production by human eosinophils. Eosinophils (10⁶/ml) were stimulated for 1 h at 37°C with concentrations of PAF or vehicle alone. Data are means ± SEM of eicosanoids formed by eosinophils and lipid body numbers in eosinophils from six to eight independent experiments. Increasing numbers of lipid bodies correlated with 10° increased production of each eicosanoid (r > 0.97, P < 0.03 for both, Fisher's r to z transformation). *Statistically significant differences (P < 0.05, paired t test) between PAF and the vehicle. LTC₄ and PGE₂ in supernatants were measured by ELISA after incubation with 0.5 μM A23187 for 15 min.

**Figure 6.** Eosinophil cytoplasts and immunolocalization of eicosanoid-forming enzymes. Freshly isolated eosinophils (A), eosinophil cytoplasts (B), and karyoplasts (C) were fixed in methanol and stained with Diff-Quik (Baxter Healthcare Corp., Miami, FL). Eosinophil cytoplasts were incubated with PAF (1 μM, for 1 h) to induce lipid body formation. 5-LO (D), LTC₄ synthase (E), and COX (F) were localized at cytoplast lipid bodies using specific anti-5-LO rabbit antiserum, affinity-purified rabbit IgG anti-LTC₄ synthase, or anti-COX, respectively, and glucose-oxidase immunocytochemistry. Substitution of the primary antibody by nonimmune rabbit serum (G) or rabbit IgG (H) were controls.
tussis toxin significantly inhibited PAF-induced lipid body formation. In agreement, PAF-induced lipid body formation was dose dependently inhibited by the PAF receptor antagonist WEB 2086. Moreover, G protein-coupled PAF receptor signaling is pertussis toxin sensitive (35), and pertussis toxin significantly inhibited PAF-induced lipid body formation. In addition to PAF receptor-initiated signaling, additional downstream intracellular signaling pathways were involved in eosinophil lipid body formation. A role for PKC mediation of lipid body formation has been indicated in studies using neutrophils (25, 36). In eosinophils, the abilities of staurosporine, H-7, and two highly selective PKC inhibitors (chelerythrine, which interacts with the catalytic domain, and calphostin C, which acts on the regulatory domain of PKC) to inhibit lipid body induction are consistent with involvement of PKC in PAF-induced lipid body formation. Further, inhibitors of transcription (actinomycin D) and translation (cycloheximide) significantly inhibited lipid body formation induced by PAF, thus indicating that the stimulated induction of lipid bodies depends on new protein synthesis and suggesting that early response genes are activated during the process of lipid body formation.

The definition that eosinophil lipid bodies can be rapidly induced by PAF-initiated signaling is in accord with studies in neutrophils which also have demonstrated that specific signaling pathways lead to rapid lipid body induction (24, 25). However, these findings do not define how lipid bodies may participate in enhanced eicosanoid synthesis. If lipid bodies are to have roles in eicosanoid mediator formation, then the arachidonic acid present in those lipid-rich structures must be liberated by phospholipases. Consistent with regulated release of arachidonate occurring directly at lipid bodies, we have recently demonstrated the cocompartmentalization of MAP kinases and cPLA\textsubscript{2}, the upstream enzymes involved in arachidonic acid liberation, within lipid bodies in U 937 cells (Yu, W., P.T. Bozza, D.M. Tzizik, J.P. Gray, J. Cassara, A.M. Dvorak, and P.T. Weller, manuscript submitted for publication). Similarly, cPLA\textsubscript{2}
can be demonstrated by immunocytochemistry at eosinophil lipid bodies (not shown).

If arachidonate is liberated intracellularly at lipid bodies, then either arachidonate must be translocated to sites of eicosanoid synthesis or eicosanoid formation must occur directly at lipid bodies. Previous studies on the intracellular localization of 5-LO have shown that 5-LO localization is cell type specific and may vary according to the activation state of the cell (6–10). 5-LO has been localized within the nuclear environment (perinuclear membrane and euchromatin) of some cell types, including alveolar macrophages and basophilic leukemia cells (9, 10). Using cell fractionation with immunoblotting, 5-LO was found to be predominantly cytosolic in human neutrophils (9) and resting peritoneal macrophages (37), although after activation 5-LO could also be found in the nuclear membranes of these cells. Stimulated leukocytes metabolize arachidonic acid via the 5-LO pathway to form LTA₄, which can degrade non-enzymatically to form 6-trans isomers of LTB₄ or can be enzymatically converted to LTB₄ or LTC₄ (for review see reference 1). Upon stimulation, human eosinophils preferentially produce LTC₄ as their 5-LO pathway product (31). LTC₄ synthase is the terminal LTC₄-forming enzyme and is present selectively in eosinophils, basophils, and mast cells (31, 38, 39). In human eosinophils, the coupling of LTA₄ synthesis with LTC₄ synthesis is highly efficient since the 6-trans isomers of LTB₄ do not form in ionophore-stimulated eosinophils, as they do in neutrophils (31). Human eosinophils also generate COX-derived eicosanoids (40), albeit in lesser quantities than LTC₄. Although COX localization is undefined in eosinophils, in other cells COX isoforms have been localized to the endoplasmic reticulum and the perinuclear membrane (3–5). Thus, in human eosinophils the key eicosanoid-forming enzymes are 5-LO, LTC₄ synthase (potentially coupled in some fashion with 5-LO to form LTC₄), and COX.

By means of immunocytochemistry and ultrastructural postembedding immunogold, we have now shown that all three key eicosanoid-forming enzymes in human eosinophils, 5-LO, LTC₄ synthase, and COX, are localized directly at lipid bodies in eosinophils. The three enzymes are present both in naturally formed eosinophil lipid bodies and, of importance, to the capacity of lipid bodies to participate in enhanced eicosanoid mediator formation, in PAF-induced lipid bodies which are formed rapidly (within 1 h) in intact and anucleate human eosinophils. In intact eosinophils, anti-5-LO staining was present in the perinuclear and cytosolic regions, consistent with previous observations in other cells (9, 10), and was specifically found at lipid bodies, identified by their incorporation of fluorescent fatty acids (Fig. 2, A and B). Ultrastructural immunogold localization of 5-LO in naturally formed lipid bodies in eosinophils from an HES donor corroborated this localization and further suggested that 5-LO was distributed within the lipid bodies and not principally at their periphery (Fig. 3). Similarly to that observed for 5-LO, LTC₄ synthase was shown to colocalize at lipid bodies (Fig. 4, C and D). Immunochemistry of PAF-stimulated eosinophils using an anti-COX polyclonal antibody demonstrated diffuse perinuclear and cytoplasmic staining, consistent with previous studies which reported perinuclear and endoplasmic reticulum localization of COX (3–5), as well as distinct punctate anti-COX staining which precisely colocalized with fluorescent fatty acid-labeled lipid bodies (Fig. 4, C and D). In agreement, COX has been previously localized by immunogold electron microscopy within naturally formed lipid bodies in eosinophils and other cell types (21–23, 41). Leukocytes can express two isoforms of COX: COX-1 (the constitutive enzyme), and COX-2 (an inducible form in most cells). Since the anti-COX antibody used in this study does not discriminate between the two COX isoforms, further studies are necessary to establish the isoform present in PAF-induced lipid bodies. The compartmentalization of three key eicosanoid-forming enzymes at lipid body domains in eosinophils (Figs. 2–4, 6), even within an hour of their induced formation, together with esterified arachidonic substrate (17, 20) and cPLA₂, provides in one inducible locale an efficient topographic means to regulate arachidonic release and directly couple it with the requisite eicosanoid-forming enzymes.

Stimuli known to prime leukocytes for enhanced eicosanoid generation, including PKC activators, arachidonate, and PAF (24, 25, 42–44), are also active in inducing lipid body formation (24, 25, 36). Consistent with roles for lipid bodies in enhanced formation and release of eicosanoids, we demonstrated significant correlations between levels of PAF-induced lipid body formation and amounts of enhanced LO- and COX-derived eicosanoids generated by human eosinophils (Fig. 5). Analogous enhancement of eicosanoid production by eosinophils has been observed after lipid body induction by αs-fatty acids (24). Conversely, agents which inhibited lipid body formation also resulted in inhibited priming for eicosanoid production. Pretreatment of eosinophils with the protein synthesis inhibitors actinomycin D or cycloheximide, inhibited not only PAF-induced lipid body formation, but also priming for increased LTC₄ and PGE₂ release by eosinophils To ascertain that PAF induction of lipid body formation and priming for enhanced eicosanoid formation was truly independent of any nuclear pools of eicosanoid-forming enzymes or lipids, eosinophil enucleated cytoplasts were prepared. As observed with intact eosinophils, PAF induced dose-dependent increases in the number of lipid bodies in eosinophil cytoplasts. Likewise, PAF-induced lipid body formation in nuclei-free cytoplasts strongly correlated with increased LTC₄ and PGE₂ production after submaximal stimulation with A23187 (Fig. 7), and PAF-induced eosinophil cytoplast lipid bodies were sites of 5-LO, LTC₄ synthase, and COX localization (Fig. 6). Further evidence for the localization of 5-LO at lipid bodies was obtained by immunoblotting of isolated eosinophil subcellular fractions. After PAF stimulation of lipid body formation, 5-LO was strongly present in isolated lipid bodies (Fig. 8). In both unstimulated and 5-LO-stimulated eosinophils, 5-LO was abundant in the cytosol but not in the microsomal and...
nuclear fractions. Thus, lipid bodies are nuclear-independent sites at which enhanced formation of eicosanoids may occur.

Our findings indicate that lipid bodies are inducible, cytoplasmic sites for eicosanoid-forming enzyme localization and eicosanoid production. Together with recent findings indicating that the nucleus and perinuclear membrane may also function as important sites for eicosanoid metabolism (5, 11), our findings of a distinct role for lipid bodies as extranuclear sites for eicosanoid formation may be indicative of differential intracellular compartmentalization of eicosanoid synthesis related to the autocrine or paracrine activities of the eicosanoids. Eicosanoids formed within or around the nucleus may function as autocrine regulators of transcription or other processes. In contrast, lipid bodies, as rapidly inducible structures which provide sources of arachidonate at sites for regulated arachidonate release coupled intimately with eicosanoid-forming enzymes, are likely to have specific roles in the generation of eicosanoids with paracrine mediator activities. The prominence of lipid bodies in leukocytes in vivo in association with a variety of inflammatory pathological conditions (12–15, 17–19), many of which are known to have enhanced generation of arachidonic acid products, such as LTs and PGs, would be compatible with this role for lipid bodies. In conclusion, our results indicate that lipid bodies are rapidly inducible, specialized cytoplasmic domains for eicosanoid-forming enzyme localization which may have specific roles in enhanced paracrine eicosanoid mediator formation during inflammatory processes.

We thank Dr. Jilly Evans for purified recombinant 5-LO and anti-5-LO antiserum and Jennifer P. Gray, Daniel T. Zizik, and Jessica Cassara for technical assistance.

This work was supported by National Institutes of Health grants AI-22571, AI-20241 and AI-33372. P.T. Bozza is a PEW Fellow in Biomedical Sciences, and is a recipient of postdoctoral fellowship from CNPq (Brazilia, Brazil).

Address correspondence to Dr. Peter F. Weller, Beth Israel Deaconess Medical Center, 330 Brookline Ave., DA-617, Boston, MA 02215. Phone: 617-667-3307; FAX: 617-277-6061; E-mail: pweller@bidmc.harvard.edu

Received for publication 25 March 1997 and in revised form 11 July 1997.

References

1. Serhan, C.N. 1994. Eicosanoids in leukocyte function. Curr. Opin. Hematol. 1:69–77.
2. Henderson, W.R., Jr. 1994. the role of leukotrienes in inflammation. Ann. Intern. Med. 121:684–697.
3. Morita, I., M. Schindler, M.K. Regier, J.C. Otto, T. Hori, D.L. DeWitt, and W.L. Smith. 1995. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:10902–10908.
4. Otto, J.C., and W.L. Smith. 1994. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J. Biol. Chem. 269:19868–19875.
5. Smith, W.L., R.M. Garavito, and D.L. DeWitt. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenase-1 and -2). J. Biol. Chem. 271:33157–33160.
6. Rouzer, C.A., and S. Kargman. 1988. Translocation of 5-Lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem. 263:10980–10988.
7. Woods, J.W., J.F. Evans, D. Ethier, S. Scott, P.J. Vickers, L. Kern, J.A. Hebein, S. Charlestone, and I.I. Singer. 1993. 5-Lipoxygenase and 5-lipoxygenase–activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 178:1935–1946.
8. Reid, G.K., S. Kargman, P.J. Vickers, J.A. Mancini, C. Levyle, D. Ethier, D.K. Miller, J.W. Gillard, R.A. Dixon, and J.F. Evans. 1990. Correlation between expression of 5-lipoxygenase–activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J. Biol. Chem. 265:19818–19823.
9. Brock, T.G., R. Paine III, and M. Peters-Golden. 1994. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J. Biol. Chem. 269:22059–22066.
10. Woods, J.W., M.J. Coffey, T.G. Brock, I.I. Singer, and M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 95:2035–2046.
11. Serhan, C.N., 1996. Signalling the fat controller. Nature (Lond.). 384:23–24.
12. Coimbra, A., and A. Lopes-Vaz. 1971. The presence of lipid droplets and the absence of stable sudanophilia in osmium-fixed human leukocytes J. Histochem. Cytochem. 19:551–557.
13. Shlesinger, P.A., M.T. Stilman, and L. Peterson. 1982. Polyarthritis with birefringent lipid within synovial fluid microphages: case report and ultrastructural study. Arthritis Rheum. 25:1365–1368.
14. Weller, J., 1890. Synovial fluid leukocytes associated with intracellular lipid inclusions. Arch. Inten. Med. 140:560–561.
15. Triggiani, M., A. Oriente, M.C. Seeds, D.A. Baas, G. Arone, and F.H. Chilton. 1995. Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. J. Exp. Med. 182:1181–1190.
16. Robinboin, J.M., M.L. Karnovsky, and M.J. Karnovsky. 1982. Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation. J. Cell Biol. 95:933–942.
Dvorak. 1991. Cytoplasmic lipid bodies of human eosinophils: subcellular isolation and analysis of arachidonate incorporation. Am. J. Pathol. 138:141–148.

18. Solley, G.O., J.E. Maldonado, G.J. Gleich, E.R. Giuliani, H.C. Hoagland, R.V. Pierce, and A.L. Brown, Jr. 1976. Endomyocardial disease in the human. Mayo Clin. Proc 51: 697–708.

19. Beil, W.J., P.F. Weller, M.A. Peppercomb, and A.M. Dvorak. 1995. Ultrastructural immunogold localization of subcellular sites of TNF-α in colonic Crohn’s disease. J. Luekozyt Biol. 58:284–298.

20. Weller, P.F., S.J. Ackerman, A. Nicholson-Weller, and A.M. Dvorak. 1989. Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am. J. Pathol. 135:947–959.

21. Dvorak, A.M., E. Morgan, D.M. Tzizik, and P.F. Weller. 1994. Prostaglandin endoperoxide synthase (cyclooxygenase): ultrastructural localization to nonmembrane-bound cytoplasmic lipid bodies in human eosinophils and murine 3T3 fibroblasts. Int. Arch. Allergy Immunol. 105:245–250.

22. Dvorak, A.M., E. Morgan, R.P. Schleimer, S.W. R yeom, L.M. Lichtenstein, and P.F. Weller. 1992. Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to nonmembrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes and neutrophils. J. Histoch. Cytoderm. 40:759–769.

23. Dvorak, A.M., R.P. Schleimer, H.F. Dvorak, L.M. Lichtenstein, and P.F. Weller. 1992. Human lung mast cell and alveolar macrophage cytoplasmic lipid bodies contain arachidonic acid and prostaglandin endoperoxide synthase (cyclooxygenase), the substrate and enzyme necessary for prostaglandin production. Int. Arch. Allergy Immunol. 99:208–217.

24. Bozza, P.T., J.L. Payne, S.G. Morham, R. Langenbach, O. Smithies, and P.F. Weller. 1996. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Proc. Natl. Acad. Sci. USA. 93:11091–11096.

25. Bozza, P.T., J.L. Payne, J.L. Goulet, and P.F. Weller. 1996. Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. J. Exp. Med. 183:1515–1525.

26. Penrose, J.F., J. Spector, B.K. Lam, D.S. Friend, R.M. Jack, and K.F. Austen. 1995. Purification of human lung leukotriene C4 synthase and preparation of a polyclonal antibody. A m. J. Respir. Crit. Care Med. 152:283–289.

27. Hansel, T.T., I.J.M. de Vries, T. Iff, S. Rhi ls, M. Wandelizak, S. Betz, K. Blaser, and C. Walker. 1991. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. 140:147–150.

28. Rhee, D., A.A. Voetman, and L.J. Meerhof. 1983. Functional activity of enucleated human polymorphonuclear leucocytes. J. Cell Biol. 97:368–377.

29. Qu-Hong, L.F. Brown, H.F. Dvorak, and A.M. Dvorak. 1997. Ultrastructural immunogold localization of osteopontin in human gastric mucosa. J. Histoch. Cytoderm. 45:21–33.

30. Pagano, R.E., and R.G. Slieght. 1985. Defining lipid transport pathways in animal cells. Science (Wash. D.C.) 229:1051–1057.

31. Weller, P.F., C.W. Lee, D.W. Foster, E.J. Corey, K.F. Austen, and R.A. Lewis. 1983. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils. Proc. Natl. Acad. Sci. USA. 80:7626–7630.

32. Penrose, J.F., L. Gagnon, M. Goppelt-Strube, P. Myers, B.K. Lam, R.M. Jack, K.F. Austen, and R.J. Soberman. 1992. Purification of human leukotriene C4 synthase. Proc. Natl. Acad. Sci. USA. 89:11603–11606.

33. Lam, B.K., J.F. Penrose, G.J. Freeman, and K.F. Austen. 1994. Expression cloning of a CDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. USA. 91:7663–7667.

34. Braquet, P., L. Touqui, T. Shen, and B.B. Vargaftig. 1987. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39:2–97.

35. Murphy, P.M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:593–633.

36. Weller, P.F., S.W. Ryeom, S.T. Picard, J. Ackerman, and A.M. Dvorak. 1991. Cytoplasmic lipid bodies of neutrophils: induction and eicosanoid formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. J. Exp. Med. 183:1515–1525.

37. Peters, M., and R.W. McNish. 1993. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196:147–153.

38. McGlashan, D., Jr., R.P. Schleimer, S.P. Peters, E.S. Schumalan, G.K. Adams III, N.H. Newball, and L.M. Lichtenstein. 1982. Generation of leukotrienes by purified human lung mast cells. J. Clin. Invest. 70:747–751.

39. McGlashan, D., Jr., S.P. Peters, J. W arner, and L.M. Lichtenstein. 1986. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimer cross-links. J. Immunol. 136:2231–2236.

40. Parsons, W.G. III, and L.J. Roberts II. 1988. Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils A potential mast cell-eosinophil interaction. J. Immunol. 141:2413–2419.

41. Dvorak, A.M., M.E. Hammond, E.S. Morgan, and H.F. Dvorak. 1980. Ultrastructural studies of macrophages in vitro. The formation of cell coat with macrophage inhibition factor (MIF)-containing lymphocyte culture supernatants: chloroform extraction, phospholipase digestion, and autoradiographic studies. J. R etiology. Soc. 27:119–142.

42. Bauldry, S.A., R.L. Wylke, and D.A. Bass. 1988. Phospholipase A2 activation in human neutrophils. Differential actions of diacylglycerols and alkylacylglycerols in priming cells for stimulation by N-formyl-met-leu-phe. J. Biol. Chem. 263: 16787–16795.

43. Bauldry, S.A., R.L. Wylke, and D.A. Bass. 1991. Differential actions of diacyl- and alkylacylglycerols in priming phospholipase A2, 5-lipoxygenase and acetyltransferase activation in human neutrophils. Biochim. Biophys. Acta. 1084:178–184.

44. Stewart, A.G., P.N. Dubbin, T. Harris, and G.J. Dusting. 1990. Platelet-activating factor may act as a second messenger in the release of iocosanoids and superoxide anions from leukocytes and endothelial cells. Proc. Natl. Acad. Sci. USA. 87: 3215–3219.

920 Lipid Bodies: Inducible Sites for Eicosanoid Formation